Objectives: Prostate cancer is one of the most frequent malignancies in men, worldwide, although its underlying mechanisms are not fully understood. Long non-coding RNAs participate in development of human cancers. In this invetsigation, we aimed to study the roles of lincRNA-p21 in development of human prostate cancer. Results: LincRNA-p21 was found to be down-regulated in human prostate cancer, and low levels of lincRNA-p21 correlated with high disease stage and prediction of poor survival. We further showed that lincRNA-p21 inhibited prostate cancer cell proliferation and colony formation in vitro and reduced rate of prostate cancer cell population growth in vivo. Study of mechanisms involved revealed that lincRNA-p21 promoted apoptosis and induced expression of p53 downstream genes by regulating p53 binding to their promoters. Finally, we showed that expression of p53 downstream genes was reduced in the malignant prostate tissues, which correlated with lincRNA-p21 level.
molecular processes, including cell differentiation, lineage specificity, neurological disorders and cancer. [6] [7] [8] In human prostate cancer, the first prominent lncRNA, PCA3, was initially described as a novel biomarker of prostate cancer, 9 and subsequently defined as a promising urine test for this disease. 10 Similarly, the lncRNAs PCGEM1,
11
SChLAP1, 12 PCAT-1 13, 14 and PCAT-3 15 have been implicated in prostate cancer.
LincRNA-p21 is a p53-regulated long intragenic non-coding RNA that has been proposed to act in trans via several mechanisms including repressing genes in the p53 transcriptional network and regulating mRNA translation and protein stability. 16 The physiological and pathological functions of lincRNA-p21 were gradually defined. For example, lincRNA-p21 has been identified as a regulator for the Warburg effect and as a valuable therapeutic target for cancer. 17 In the vascular system, lincRNA-p21 regulated neointima formation, vascular smooth muscle cell proliferation, apoptosis and atherosclerosis by enhancing p53 activity. 18 The functions of lincRNA-p21 in regulating of stem cell pluripotency were also been identified. 19, 20 A previous report showed that exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with prostate cancer. 21 However, the physiological and pathological roles of lincRNA-p21 in the prostate cancer remain unknown.
Here, we demonstrate that lincRNA-p21 suppresses the development of human prostate cancer. LincRNA-p21 is down-regulated in human prostate cancer tissues, and low lincRNA-p21 level predicts poor survival. Furthermore, we show that lincRNA-p21 inhibits prostate cancer growth in vitro and in vivo. LincRNA-p21
induces apoptosis in prostate cancer cells. In addition, lincRNA-21
promotes p53 enrichment at the promoters of its target genes and thus regulates the expression of p53 downstream proapoptotic genes. Finally, we show that the down-regulation of p53 downstream genes is associated with lincRNA-p21 in human prostate cancer tissues.
| MATERIALS AND METHODS

| Patients
Two separate cohorts of patients were included in this study. In 
| Quantitative real-time PCR
Total RNA was extracted from prostate cancer cells or human normal prostate or prostate cancer tissues with TRIzol (Invitrogen).
The cDNA was synthesized from 1 μg of total RNA with One
Step RT-PCR Kit (Takara). Real-time PCR was performed with the SYBR Green (Takara) detection method on an ABI-7500 RT-PCR system (Applied Biosystems). The primers used for real-time PCR are listed in Table 3 .
| Western blot
Whole-cell extracts were obtained by lysing cells in TNTE buffer (50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L sodium pyrophosphate, 0.5% Triton X-100, 1 mmol/L sodium vanadate and 25 mmol/L sodium fluoride) containing protease inhibitors (5 μg/ml PMSF, 0.5 μg/ml leupeptin, 0.7 μg/ ml pepstatin and 0.5 μg/ml aprotinin). The detailed Western blot procedures have been described previously. 17 The protein samples were analysed using antibodies against Mdm2 (Abcam), Puma 
| Cell culture and retroviral transduction
The human prostate cancer cell lines LNCaP, DU145 and PC3 were obtained from the American Type Culture Collection (ATCC), PTN2
from Sigma and BPH-1 from YRGenge, and they were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FBS (Gibco).
Sh-lincRNA-p21 and control shRNA (sh-Ctrl) lentivirus particles were purchased from GenePharma. The shRNA sequence targeting lincRNA-p21 is 5′-GGAGGACACAGGAGAGGCA-3′. Lentivirus expressing human lincRNA-p21 was generated by subcloning human lincRNA-p21 cDNA to the pSLIK lentivirus expression system. For retroviral packaging, 293T cells were co-transfected with the retroviral particles. For transduction, LNCaP, PC-3 and DU145 cells were incubated with virus-containing supernatant in the presence of 8 mg/ ml polybrene. After 48 hours, infected cells were selected for 72 hours with puromycin (1.5 mg/ml) or hygromycin (150 mg/ml).
| Cell proliferation and colony formation assay
Cell proliferation rate was monitored by CCK-8 Cell Proliferation/ Viability Assay Kit (Sigma) according to the guidelines.
For colony formation assay, prostate cancer cells were suspended in 1.5 ml complete medium supplemented with 0.45% low melting point agarose (Invitrogen). The cells were placed in 35 mm tissue culture plates containing 1.5 mL complete medium and agarose (0.75%) on the bottom layer. The plates were incubated at 37°C with 5% CO 2 for 2 weeks. Cell colonies were stained with 0.005% crystal violet and analysed using a microscope.
| Apoptotic assay
Apoptosis was monitored by Fluorescence Activated Cell Sorter T A B L E 3 Primers used for real-time PCR Name Sense (5′-3′) Antisense (5′-3′)
| Tumour xenograft experiments
8-10 mm in diameter, they were prepared to form a brei and then injected subcutaneously into nude mice. Tumour growth was monitored using calipers each 3 days or by tumour weight at the end of study (4 weeks for in vivo tumour growth). The study was approved by the Animal Research Ethics Committee of Shanghai Jiaotong University.
The methods were carried out in accordance with the approved guidelines.
| Chromatin immunoprecipitation (ChIP) assay
Cells were cross-linked by adding formaldehyde to a final concentration of 1% at room temperature for 10 min. After washing four times with 20 ml PBS in 50 ml conical tubes, cells were scraped and 
| Statistical analysis
All values are expressed as the mean±SEM. Statistical differences between two groups were determined using Student's t test. Oneway ANOVA was applied to analyse data that are more than two groups. The correlation of lincRNA-p21 level with patients' clinicopathological variables was analysed by the chi-square test or Fisher's exact test. The Kaplan-Meier method was used to estimate overall survival. Survival differences according to lincRNA-p21 expression were analysed by the log-rank test. Linear regression analysis was used to analyse the relationship between lincRNA-p21 and p53 downstream genes. P value of less than 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism 6.
| RESULTS
| LincRNA-p21 is down-regulated in prostate cancer and predicts survival
To investigate the potential role of lincRNA-p21 in human prostate cancer, we first tested the expression pattern of lincRNA-p21 in human prostate cancer. The relative expression of lincRNA-p21 in normal human prostate tissues and human prostate cancer tissues were analysed. We found that lincRNA-p21 level was significantly downregulated in prostate cancer tissues compared with normal prostate tissues (Fig. 1A) . We also analysed the expression of lincRNA-p21 in prostate cancer tissues and matched adjacent normal prostate tissues.
The results also revealed that lincRNA-p21 in prostate cancer tissues were lower than that in adjacent normal prostate tissues (Fig. 1B) . (Table 1 ). In addition, we analysed the correlation between lincRNA-p21 level and patients' survival. The survival analysis showed that low lincRNA-p21 level predicts both overall and disease-free survival ( Fig. 2A,B) . These findings were also validated (Table 2 and Fig. 2C,D) . Therefore, lincRNA-p21 may act as a prognostic factor for human prostate cancer.
| LincRNA-p21 regulates proliferation and colony formation of prostate cancer cell growth in vitro
The significant correlation between lincRNA-p21 and human prostate cancer prompted us to investigate the role of lincRNA-p21 in human prostate cancer. To this end, we first tested the function of lincRNAp21 in cellular proliferation and colony formation. We knocked down lincRNA-p21 in three prostate cancer cell lines, LNCaP, PC-3 and DU145 cells (Fig. 3A) and found that lincRNA-p21 knockdown facilitated the proliferation rate of prostate cancer cells (Fig. 3B-D) .
We also overexpressed lincRNA-p21 in these three prostate cancer cell lines (Fig. 3E) , and the results showed that lincRNA-p21 overexpression inhibited prostate cancer cell proliferation (Fig. 3F-H) . We next investigated whether lincRNA-p21 could affect the capacity of colony formation of prostate cancer cells. Significantly, lincRNAp21 knockdown promoted cellular colony formation (Fig. 4A-D) , whereas lincRNA-p21 overexpression reduced the ability of colony formation in prostate cancer cells (Fig. 4E-G) . Taken together, these data provide in vitro evidence that lincRNA-p21 inhibits cellular proliferation and colony formation of human prostate cancer cells.
| LincRNA-p21 regulates prostate cancer development in vivo
To further investigate the effect of lincRNA-p21 on prostate cancer growth in vivo, we performed xenograft experiments using LNCaP cells with/without lincRNA-p21 stable knockdown. We found that lincRNA-p21 knockdown markedly increased the growth rate of LNCaP cell in vivo from 3 weeks post LNCaP cell injection subcutaneously (Fig. 5A ). In addition, we analysed the tumour size and weight at the end of xenograft experiments. The results showed that lincRNA-p21 knockdown strictly promoted tumour growth, as evidenced by increased tumour size and weight in the lincRNA-p21 knockdown group compared with the control (Fig. 5B,C) . In conclusion, lincRNA-p21 knockdown promotes prostate cancer cell growth in vivo.
| LincRNA-p21 regulates apoptosis of prostate cancer cells
LincRNA-p21 was previously reported to regulate cell survival and apoptosis, and we wanted to know whether lincRNA-p21 targeted apoptosis in prostate cancer. We overexpressed lincRNA-p21 in prostate cancer cells and found that lincRNA-p21 overexpression was able to induce apoptosis in prostate cancer cells (Fig. 6A,B) . In addition, the TUNEL assay also indicated that lincRNA-p21 overexpression increased the percentage of TUNELpositive cells (Fig. 6C) . We also tested the expression of several markers that promote apoptosis. We found that lincRNA-p21 overexpression increased the expression of Mdm2, Puma, Noxa and Bax at both mRNA and protein levels (Fig. 6D,E) , whereas lincRNA-p21 knockdown obtained opposite results (Fig. 6F,G ).
These findings implicate that lincRNA-p21 induces apoptosis in prostate cancer cells, which may depend on the regulation of proapoptotic proteins.
| LincRNA-p21 targets p53 in prostate cancer
Previous reports have shown that lincRNA-p21 can function through regulating p53 transcriptional activity, 18 and we showed that lincRNA-p21 promoted the expression of p53 downstream Mdm2, Puma, Noxa and Bax ( Fig. 6D-G (Fig. 7A) , whereas the enrichment of p53 was inhibited by lincRNA-p21 knockdown (Fig. 7B) .
These results indicate that lincRNA-p21 may regulate p53 enrichment at the promoters of Mdm2, Puma, Noxa and Bax to mediate their expression and apoptosis. Finally, we tested the expression of Mdm2, Puma, Noxa and Bax expression in human prostate cancer tissues. We found that the mRNA levels of Mdm2, Puma, Noxa and Bax were significantly down-regulated in human prostate cancer tissues compared with normal prostate cancer tissues (Fig. 8A-D) .
Interestingly, we found that the mRNA levels of Mdm2, Puma, Noxa and Bax were significantly and positively correlated with the level of lincRNA-p21 in human prostate cancer (Fig. 8E-H) . In summary,
lincRNA-p21 regulates p53 and its downstream genes in human prostate cancer.
| DISCUSSION
In the present work, we provide evidence that lincRNA-p21 acts as a tumour suppressor in human prostate cancer. The lincRNA-p21 level is reduced in human prostate cancer and low level of lincRNA-p21 is associated high disease stage and poor survival of patients. By using loss-of-function and gain-of-function strategies, we demonstrate that lincRNA-p21 inhibits prostate cancer growth in vitro and in vivo.
Furthermore, we show that lincRNA-p21 induces apoptosis, and expression of p53 downstream genes partly through regulating the DNA-binding capacity of p53.
Long non-coding RNAs play diverse roles in human carcinoma. 6, 7 In human prostate cancer, several long non-coding RNAs have been via the PSF-dependent mechanism, thus promoting cell cycle progression. 22 Here, we identify lincRNA-p21 as a tumour suppressor in human prostate cancer partly through regulating apoptosis.
LincRNA-p21 is long intragenic non-coding RNA directly induced by p53 and plays a critical role in the p53 transcriptional response. 16 Both protein and mRNA targets for lincRNA-p21 have been identified. 16 Here, we showed the proapoptotic role of lincRNA-p21 in human prostate cancer cells. LincRNA-p21 overexpression induced apoptosis in prostate cancer cells, which may partly account for the repression of cell growth in vitro and in vivo mediated by lincRNA-p21. However, lincRNA-p21 was also reported to regulate cell cycle 16, 20 ; therefore, we could not exclude the possibility that lincRNA-p21 inhibits prostate cancer cell growth through blocking cell cycle. In macrophages and human arterial vascular smooth muscle cells, lincRNA-p21 could bind to the p53 upstream Mdm2, which antagonizes p53 by enhancing its degradation via the ubiquitin-proteasome pathway and by blocking its binding and acetylation by p300. 18 Interaction of lincRNA-p21 with Mdm2 inhibits Mdm2-p53 interaction, thus leads to p53 hyperacetylation and transactivation. Indeed, we found that lincRNA-p21 promotes p53 binding to the promoters of its downstream proapoptotic genes (Mdm2, Puma, Noxa and Bax), thus increased their expression and may promote apoptosis. Interestingly, we found that the expression of these apoptotic genes was down-regulated in human prostate cancer tissues and their mRNA levels were positively correlated with lincRNA-p21 level.
In conclusion, lincRNA-p21 serves as a tumour suppressor in human prostate cancer partly through regulating p53. LincRNA-p21 may be a potential prognostic marker and candidate drug target for prostate cancer.
